FDAsafety guidance77% confidence
Wizcure Pharmaa Private Limited - 726378 - 06/24/2026
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Urology · 5-alpha reductase inhibitor
- Sub-indication
- General
Related signal: Aurobindo Pharma's Finasteride ANDA078341 Receives AP Status